ArticleCancer cell international2025
PTDSS1 serves as a prognostic biomarker of macrophage infiltration in pan-cancer and promotes hepatocellular carcinoma malignant phenotypes.
Article in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundPhosphatidylserine synthase 1 (PTDSS1) inhibitor has been developed and shows promising anti-tumor effect, but existing studies about PTDSS1 remain limited in cancer.
methodsThis study preliminarily analyzed the differential expression, prognostic significance, copy number variation, methylation level, co-expression network and immune correlation of PTDSS1 in pan-cancer. Furthermore, we collected tumor samples and corresponding clinical information of 74 hepatocellular carcinoma (HCC) patients from the First Hospital of Guangxi Medical University (Guangxi cohort) to validate PTDSS1 expression and prognostic value. In vitro experiments were performed to investigate the effect of PTDSS1 knockdown on the malignant phenotypes of HCC cell lines.
resultsThis study identified that PTDSS1 was significantly upregulated across most cancer types and associated with poor prognosis of seven cancer types. Copy number amplification and hypermethylation of PTDSS1 may drive its upregulation. Furthermore, PTDSS1 exhibited a positive correlation with macrophage in various cancers, co-expression network and functional enrichment analysis revealed that PTDSS1 may involve in cell division, cell cycle, DNA repair, cell proliferation, cell migration, cell growth, immune response and WNT signaling pathway. Regarding HCC, the differential expression and prognostic significance of PTDSS1 were verified by Guangxi cohort, single cell sequencing analysis revealed PTDSS1 located in tumor cell and macrophages. In vitro experiments demonstrated that PTDSS1 knockdown suppressed the proliferation, migration, invasion of HCC cells and promoted macrophage repolarization towards the M1 phenotype.
conclusionsPTDSS1 serves as a diagnostic and prognostic biomarker associated with macrophage infiltration, and may be a promising therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.